Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Effects Reverse Stock Split and Announces the Completion of and Final Exchange Ratio for the Business Combination Transaction With Biota Holdings Limited

ROCKVILLE, Md., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today the effectiveness of its six-to-one reverse stock split (the "

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Third Quarter 2012 Financial Results

ROCKVILLE, Md., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the three-month period ended September 30, 2012. The Company reported a net loss of $4.1 million, or $0.12 per share, compared to net income of $0.1 million, or zero per share, for the prior year period.

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Special Cash Dividend

ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that Nabi's Board of Directors declared a special cash dividend in the aggregate of approximately $31.4 million, $1.108 per share of Nabi common stock. The special cash dividend is payable to stockholders of record on October 26, 2012 (which was announced previously) and will be paid on November 8, 2012. As previously disclosed, in connection with the proposed business combination transaction of Nabi and Biota Holdings Limited (ASX:BTA:AU), Nabi intends to return to its stockholders in the form of this special cash dividend Nabi's remaining cash in excess of the $27 million required under the transaction agreement with Biota to be held by Nabi at the completion of the transaction, after satisfying outstanding liabilities.

Nabi Biopharmaceuticals

The Board of Nabi Biopharmaceuticals Establishes Ratio for Reverse Stock Split

ROCKVILLE, Md., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that its board of directors (the "Board") has established a ratio of one share-for-every six shares of the outstanding common stock for Nabi's proposed reverse stock split of all outstanding shares of common stock. Nabi anticipates that the reverse stock split will be effective as of 4:59 p.m., Eastern Time, on November 8, 2012 (the "Effective Time") and will be reflected in the trading price of Nabi common stock at the opening of trading on November 9, 2012.

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Nabi Stockholder Meeting Results and the Approval of the Business Combination Transaction by Biota Stockholders

ROCKVILLE, Md., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today the results of the reconvened special meeting of Nabi stockholders held on October 22, 2012 (the "Nabi Special Meeting"). Nabi also announced that the stockholders of Biota Holdings Limited (ASX:BTA.AX) approved the proposed business combination transaction between Nabi and Biota at the meeting of Biota stockholders held on October 23, 2012 in Melbourne, Australia.

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Exchange Ratio for Proposed Business Combination Transaction With Biota Holdings Limited

ROCKVILLE, Md., Oct. 19, 2012 (GLOBE NEWSWIRE) -- Nabi today announced that, if the proposed business combination transaction between Nabi Biopharmaceuticals (Nasdaq:NABI) and Biota Holdings Limited (ASX:BTA.AX) is completed, each ordinary share of Biota capital stock will be transferred to Nabi in exchange for 0.749778075 of a share of Nabi common stock, subject to the adjustment described below if the proposed reverse stock split becomes effective.

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Results of NicVAX(R) Phase II Study in Combination With Varenicline

ROCKVILLE, Md., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that the phase II study of NicVAX

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Sets Record Date for Cash Dividend

ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi today announced that Nabi's Board of Directors has set October 26, 2012 as the record date with respect to the cash dividend to be paid in connection with the proposed business combination transaction of Nabi Biopharmaceuticals (Nadsaq:NABI) and Biota Holdings Limited (ASX:BTA.AX). As previously disclosed, Nabi intends to return to its stockholders in the form of a dividend Nabi's remaining cash in excess of the $27 million required under the transaction agreement with Biota to be held by Nabi at the completion of the transaction, after satisfying outstanding liabilities. 

Nabi Biopharmaceuticals

Two Major Independent Proxy Advisory Firms Recommend Nabi Biopharmaceutical Stockholders Support Amended Transaction With Biota Holdings Limited at October 22nd Reconvened Special Meeting

ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nadsaq:NABI) ("

Nabi Biopharmaceuticals

Nabi Biopharmaceuticals Announces Adjournment of Special Meeting of Stockholders Until October 22, 2012

ROCKVILLE, Md., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that its Special Meeting of Stockholders scheduled for September 24, 2012 has been adjourned to provide additional time to solicit proxies to approve the proposals (the "Proposals") set forth in Nabi's definitive proxy materials dated August 7, 2012, filed by Nabi with the U.S. Securities and Exchange Commission (the "SEC") in connection with the proposed business combination transaction between Nabi and Biota Holdings Limited (ASX:BTA.AX) (the "Transaction"). Nabi stated that it had convened the Special Meeting as originally scheduled but adjourned the meeting due to the absence of a quorum. The Special Meeting will be reconvened at The Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, Maryland on October 22, 2012, at 4:30 p.m. local time.